Lynparza

From Gilead To AstraZeneca, Investors Should Watch These Biotech Giants Right Now
Motley Fool
Thu, 05/7/20 - 10:46 am
FDA
drug approvals
Gilead Sciences
remdesivir
AstraZeneca
Merck
Lynparza
Clovis Oncology
Rubraca
Bristol-Myers Squibb
Opdivo
Yervoy
Go or no go? Oncology dominates upcoming decisions
EP Vantage
Fri, 05/1/20 - 11:09 am
FDA
oncology
AstraZeneca
Lynparza
ovarian cancer
prostate cancer
Bristol-Myers Squibb
Opdivo
lung cancer
Positive Prostate Cancer Results for Lynparza Are Bad News for Clovis Oncology
Motley Fool
Mon, 04/27/20 - 07:27 pm
Clovis Oncology
Rubraca
AstraZeneca
Merck
Lynparza
prostate cancer
AstraZeneca and Merck's Lynparza Improves Survival in Prostate Cancer with Specific Repair Gene Mutations
BioSpace
Sat, 04/25/20 - 12:10 am
AstraZeneca
Merck
clinical trials
Lynparza
metastatic castration-resistant prostate cancer
prostate cancer
AstraZeneca and Merck's string of Lynparza successes ends in ovarian cancer
BioPharma Dive
Thu, 03/12/20 - 12:58 pm
AstraZeneca
Merck
cediranib
ovarian cancer
clinical trials
Lynparza
AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer
Fierce Pharma
Mon, 01/13/20 - 11:49 pm
AstraZeneca
Merck
GSK
Lynparza
ovarian cancer
FDA
priority review
Zejula
FDA Approves New Pancreatic Treatment Found To Double Time Patients Live Without Disease Progression
Forbes
Tue, 01/7/20 - 10:34 am
FDA
Lynparza
AstraZeneca
pancreatic cancer
FDA Approves AstraZeneca and Merck's Lynparza for Pancreatic Cancer
BioSpace
Mon, 12/30/19 - 05:39 pm
AstraZeneca
Merck
Lynparza
pancreatic cancer
FDA
AZ, Merck's Lynparza narrowly snags FDA panel backing in pancreatic cancer
Fierce Pharma
Tue, 12/17/19 - 09:19 pm
AstraZeneca
Merck
Lynparza
pancreatic cancer
FDA
advisory panels
Is AZ, Merck's Lynparza approvable in pancreatic cancer sans survival benefit? FDA's about to decide
Fierce Pharma
Mon, 12/16/19 - 10:42 am
AstraZeneca
Merck
Lynparza
FDA
BRCA-mutated pancreatic cancer
pancreatic cancer
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use
Yahoo/Reuters
Sun, 09/29/19 - 11:57 am
GSK
AstraZeneca
ESMO
ovarianc cancer
PARP inhibitors
Lynparza
Zejula
AstraZeneca strengthens lead in PARP drug class
Biopharma Dive
Sat, 09/28/19 - 05:00 pm
AstraZeneca
Merck
Lynparza
ovarian cancer
PARP inhibitors
veliparib
ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win
Fierce Pharma
Sat, 09/28/19 - 04:49 pm
Roche
Avastin
ovarian cancer
AstraZeneca
Merck
Lynparza
ESMO
GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO
BioSpace
Thu, 09/26/19 - 12:33 pm
GSK
AstraZeneca
PARP inhibitors
ESMO
Lynparza
Zejula
ESMO 2019 preview – PARPs on parade
EP Vantage
Thu, 09/5/19 - 12:06 pm
ESMO
PARP inhibitors
Lynparza
AstraZeneca
ovarian cancer
GSK
Zejula
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment
Pharmaforum
Wed, 08/14/19 - 11:01 am
AstraZeneca
Merck
Lynparza
clinical trials
advanced ovarian cancer
ovarian cancer
Calquence
AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis
Yahoo/Benzinga
Wed, 08/14/19 - 10:13 am
AstraZeneca
Clovis Oncology
prostate cancer
Lynparza
AstraZeneca cancer drugs build as primary care shrinks
Biopharma Dive
Mon, 08/12/19 - 12:08 pm
AstraZeneca
cancer
oncology
primary care
Tagrisso
Symbicort
Lynparza
Clovis investors feel more Lynparza pressure
EP Vantage
Thu, 08/8/19 - 10:51 am
prostate cancer
Lynparza
Rubraca
Clovis Oncology
AstraZeneca
Merck
AstraZeneca, Merck herald PhIII prostate cancer win for Lynparza — overtaking Clovis, J&J in PARP race
Endpoints
Wed, 08/7/19 - 10:46 am
Lynparza
AstraZeenca
Merck
prostate cancer
clinical trials

Pages